TY - GEN
T1 - Effects of Beta-Blocker on Heart Rate Variability in Heart Failure with Preserved Ejection Fraction
AU - Saleem, Shiza
AU - Alkhodari, Mohanad
AU - Hadjileontiadis, Leontios J.
AU - Khandoker, Ahsan H.
AU - Jelinek, Herbert F.
N1 - Publisher Copyright:
© 2022 Creative Commons.
PY - 2022
Y1 - 2022
N2 - Heart failure is characterized by sympathetic activation and parasympathetic withdrawal leading to an abnormal autonomic modulation. Beta-blockers (BB) inhibit overstimulation of the sympathetic system and are indicated in heart failure patients with reduced ejection fraction. However, the effect of beta-blocker therapy on heart failure with preserved ejection fraction (HFpEF) is unclear. This study investigated the effect of BB therapy on heart rate variability (HRV) features as a measure of risk of an abnormal cardiac event. ECGs of seventy-three patients with HFpEF > 55% were recruited. Fifty-six patients in the BB group and 17 patients in the without BB group. HRV analysis was performed for recordings between 6-10 am and 6-10 pm, which are times associated with increased risk of cardiac events. The result shows that RMSSD (p=0.011), HF power (p=0.012), and VLF power (p=0.047) were significantly higher during the 6 - 10 am interval. Sample entropy (p=0.016), and the novel fragmentation measures PIP (p=0.015), IALS (p=0.015) and PSS(p=0.008) were significantly higher between 6 - 10 pm. Beta-blocker therapy increases HRV measures in the HFpEF group depending on the feature investigated indicating an overall decreased risk of a cardiac event and a possibly beneficial effect of beta-blockers, especially during the morning hours that is characterized by a sympathetic surge.
AB - Heart failure is characterized by sympathetic activation and parasympathetic withdrawal leading to an abnormal autonomic modulation. Beta-blockers (BB) inhibit overstimulation of the sympathetic system and are indicated in heart failure patients with reduced ejection fraction. However, the effect of beta-blocker therapy on heart failure with preserved ejection fraction (HFpEF) is unclear. This study investigated the effect of BB therapy on heart rate variability (HRV) features as a measure of risk of an abnormal cardiac event. ECGs of seventy-three patients with HFpEF > 55% were recruited. Fifty-six patients in the BB group and 17 patients in the without BB group. HRV analysis was performed for recordings between 6-10 am and 6-10 pm, which are times associated with increased risk of cardiac events. The result shows that RMSSD (p=0.011), HF power (p=0.012), and VLF power (p=0.047) were significantly higher during the 6 - 10 am interval. Sample entropy (p=0.016), and the novel fragmentation measures PIP (p=0.015), IALS (p=0.015) and PSS(p=0.008) were significantly higher between 6 - 10 pm. Beta-blocker therapy increases HRV measures in the HFpEF group depending on the feature investigated indicating an overall decreased risk of a cardiac event and a possibly beneficial effect of beta-blockers, especially during the morning hours that is characterized by a sympathetic surge.
UR - http://www.scopus.com/inward/record.url?scp=85152958684&partnerID=8YFLogxK
U2 - 10.22489/CinC.2022.225
DO - 10.22489/CinC.2022.225
M3 - Conference contribution
AN - SCOPUS:85152958684
T3 - Computing in Cardiology
BT - 2022 Computing in Cardiology, CinC 2022
PB - IEEE Computer Society
T2 - 2022 Computing in Cardiology, CinC 2022
Y2 - 4 September 2022 through 7 September 2022
ER -